Clinical Trial: A Study to Evaluate the Efficacy and Safety of LZM012 ( Psoriasis )

U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07746479) titled 'A Study to Evaluate the Efficacy and Safety of LZM012 ( Psoriasis )' on July 08.

Brief Summary: This study is a Multicenter, Open-Label, Single-Arm Phase III Clinical Trial to Evaluate the Efficacy and Safety of LZM012 Injection in Patients With Moderate to Severe Plaque Psoriasis.

Study Start Date: June 23, 2025

Study Type: INTERVENTIONAL

Condition: Psoriasis

Intervention: BIOLOGICAL: LZM012

Recombinant anti-human IL-17A/F humanized monoclonal antibody injection

Recruitment Status: COMPLETED

Sponsor: Livzon Pharmaceutical Group Inc.

Published by HT Digital Content Services with permission from Health Daily Digest....